Anti-TNF Agents for the Treatment of Rheumatoid Arthritis

Inclusion Criteria:

* Diagnosis of RA\*
* Disease duration as defined from the onset of symptoms of at least 3 months prior to study entry
* Active RA with DAS28 \> 4.4, clinically requiring the addition of anti-TNF therapy
* Stable dose of MTX between 7.5 mg and 25 mg weekly for at least 8 weeks prior to study entry
* Able and willing to self-administer subcutaneous injections or have available qualified person(s) or caregiver to administer subcutaneous injections
* For females, agree to use accepted methods of contraception during the duration of the study and for 150 days after study completion\*. \*More information on these criterion can be found in the protocol.

Exclusion Criteria:

* Positive PPD test - a tuberculosis (TB) skin test: (\> 5 mm induration regardless of prior Bacille Calmette-Guerin \[BCG\] vaccine administration) without evidence of ongoing treatment for at least 30 days or completed treatment
* History of positive PPD or chest x-ray findings indicative of prior TB infection, without documentation of either treatment for TB infection or chemoprophylaxis for TB exposure
* Prednisone dose \> 10 mg/day (or equivalent dose of another corticosteroid) within 30 days prior to study entry
* Definitive diagnosis of another autoimmune disease that may require immunosuppression for treatment\*
* Concomitant use of DMARDSs (e.g., disease-modifying antirheumatic drugs)\*
* Any immunosuppressive therapy other than MTX, NSAIDs, or corticosteroids\*
* Current or previous use of any biologic agent
* Presence of open leg ulcers
* Chronic or persistent infection that might be worsened by immunosuppressive treatment\*
* Active infection or severe infections requiring hospitalization or treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to study entry
* Received oral antibiotics, antivirals, or antifungals within 14 days prior to study entry
* Certain abnormal laboratory values\*
* Any medical condition that, in the opinion of the investigator, would interfere with the study
* History of malignancy other than treated localized carcinoma in situ of the cervix or adequately treated non-metastatic squamous or basal cell skin carcinoma within 10 years prior to study entry
* Any Investigational agent within the earlier of 4 weeks or 5 half-lives prior to study entry
* History of drug or alcohol abuse within 6 months prior to study entry
* Known allergy or hypersensitivity to study products
* Inability or unwillingness to follow the protocol
* Any condition or treatment that, in the opinion of the investigator, places the participant at an unacceptable risk
* Pregnant or breastfeeding \*More information on these criterion are in the protocol.